Table 1.
Cases of Emergency Department Visits for Hypersensitivity Reactions to Fluroquinolones, National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance, 2004–2010
| Demographic or Clinical Characteristic | Ciprofloxacin N=469 |
Levofloxacin N=505 |
Moxifloxacin N=448 |
Other FQsa N=18 |
|---|---|---|---|---|
|
| ||||
| Age | ||||
| Mean (years) ±SD | 47±19.5 | 49±18.4 | 49±15.8 | 39±19.6 |
| (Range)b | (1–98) | (13–93) | (12–90) | (7–80) |
|
| ||||
| Gender | ||||
| Male | 112 (24%) | 154 (30%) | 104 (23%) | 8 (44%) |
| Female | 357 (76%) | 351 (70%) | 344 (77%) | 10 (56%) |
|
| ||||
| Race | ||||
| White | 242 (52%) | 309 (61%) | 274 (61%) | 10 (56%) |
| Black | 59 (13%) | 49 (10%) | 21 (5%) | 2 (11%) |
| Asian | 5 (1%) | 0 (0%) | 2 (<1%) | 0 (0%) |
| Not Stated | 125 (27%) | 115 (23%) | 135 (30%) | 5 (28%) |
| Other | 38 (8%) | 32 (6%) | 16 (4%) | 1 (6%) |
|
| ||||
| Allergic Reaction Category | ||||
| Mild | 321 (68%) | 311 (62%) | 265 (59%) | 14 (78%) |
| Moderate | 123 (26%) | 158 (31%) | 155 (35%) | 4 (22%) |
| Severe | 25 (5%) | 36 (7%) | 28 (6%) | 0 (0%) |
|
| ||||
| Concomitant Medications per Case | ||||
| None Listed | 241 (51%) | 261 (52%) | 218 (49%) | 9 (50%) |
| 1–3 medications | 133 (28%) | 153 (30%) | 140 (31%) | 7(39%) |
| 4–6 medications | 64 (14%) | 57 (11%) | 60 (13%) | 2 (11%) |
| ≥ 7 medications | 31 (7%) | 34 (7%) | 30 (7%) | 0 (%) |
|
| ||||
| Disposition | ||||
| Treated and Released | 429 (91%) | 459 (91%) | 411 (92%) | 17 (94%) |
| Admitted | 24 (5%) | 32 (6%) | 24 (5%) | 0 (0%) |
| LAMAc | 12 (3%) | 5 (1%) | 6 (1%) | 1 (6%) |
| Observation in ED | 4 (1%) | 6 (1%) | 6 (1%) | 0 (0%) |
| Transferred | 0 (0%) | 3 (1%) | 1 (<1%) | 0 (0%) |
a
Gemifloxacin (n=12) and Ofloxacin (n=6),
b
There were a total of nine pediatric (<16 years) cases in the dataset distributed as ciprofloxacin (n=5), levofloxacin (n=1), moxifloxacin (n=1), gemifloxacin (n=1), and ofloxacin (n=1).
c
LAMA=left against medical advice